BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Institute of Biomedical Engineering (BME) - ECPv6.16.4.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Institute of Biomedical Engineering (BME)
X-ORIGINAL-URL:https://bme.utoronto.ca
X-WR-CALDESC:Events for Institute of Biomedical Engineering (BME)
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Toronto
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220517T120000
DTEND;TZID=America/Toronto:20220517T130000
DTSTAMP:20220517T143732Z
CREATED:20220511T143904Z
LAST-MODIFIED:20220517T143732Z
UID:36998-1652788800-1652792400@bme.utoronto.ca
SUMMARY:Global Speaker Series: Klavs Jensen\, PhD - Massachusetts Institute of Technology
DESCRIPTION:The Medicine by Design Global Speaker Series invites established and emerging international leaders in regenerative medicine to engage with our extraordinary community of researchers and clinicians.\nMedicine by Design\, in partnership with the McEwen Stem Cell Institute\, is pleased to welcome Klavs Jensen\, PhD\, Warren K. Lewis Professor\, Chemical Engineering\, and Professor\, Materials Science and Engineering\, Massachusetts Institute of Technology.\nThe title of this talk will be\, “Accelerating chemical development with automation and machine learning.”\n Register for this virtual event.  \nMore About Klavs jensen:\nKlavs F. Jensen is Warren K. Lewis Professor in Chemical Engineering and Materials Science and Engineering at the Massachusetts Institute of Technology. From 2007- July 2015 he was the Head of the Department of Chemical Engineering. His research interests include on-demand multistep synthesis\, methods for automated synthesis\, and machine learning techniques for chemical synthesis and interpreting large chemical data sets. He is a co-director of MIT’s consortium\, Machine Learning for Pharmaceutical Discovery and Synthesis\, which aims to bring machine learning technology into pharmaceutical discovery and development. Professor Jensen is a member of the US National Academy of Sciences\, the US National Academy of Engineering as well as the American Academy of Arts and Science. He is a Fellow of the American Association for the Advancement of Science (AAAS)\, and the American Institute of Chemical Engineers\, and the Royal Society of Chemistry.\n Learn more about Klavs Jensen’s lab
URL:https://bme.utoronto.ca/event/global-speaker-series-klavs-jensen-phd-massachusetts-institute-of-technology/
CATEGORIES:External Speaker Series
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220518T160000
DTEND;TZID=America/Toronto:20220518T170000
DTSTAMP:20220511T133755Z
CREATED:20220511T132357Z
LAST-MODIFIED:20220511T133755Z
UID:36981-1652889600-1652893200@bme.utoronto.ca
SUMMARY:Jump Start Workshop: Accelerate Innovation in Precision Medicine
DESCRIPTION:Event Date: Wednesday\, May 18th\, 2022; 4:00 – 5:00 pm \nThis event is hybrid\, and will be taking place on Zoom\, as well as in the Leslie Dan Faculty of Pharmacy Building in Room 850. \nRegistration required. \nDuring this session our panelists will discuss early activities that researchers should engage to accelerate innovation into technology development. Programs from Health Innovation Hub (H2I)\, University of Toronto Early-Stage Technology (UTEST) and Creative Destruction Lab (CDL) will be introduced and followed by a discussion panel. You will learn from real-world examples about where to start and how to build a technology development plan to accelerate your path towards successful fundraising and venture formation in academic settings. This session will provide insight on what to expect from an incubator or accelerator at UofT and how to gain an access to coaching\, professionals-in-residence\, and investors. This session aims to stimulate commercial thinking during research and discovery phase for everyone interested in drug\, device and platform development at UofT. \nThe goal of PRiME’s Jump Start series is to provide a comprehensive look into the essential steps involved in development of pre-clinical drugs\, devices\, and platform technologies. In the series we engage with experts to discuss important considerations to ensure success at each step of the development process. \nThese workshops are open to all Trainees and Principal Investigators at UofT. \n\n\n\n\nREGISTER HERE\n\n\n\n\nSpeakers\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n  \n  \nHassan Jaferi\, MSc\nCo-Director\, UTEST \nHassan Jaferi is the Co-Director of the UTEST incubator jointly run by the University of Toronto and the Toronto Innovation Acceleration Partners. Hassan has been involved in the creation of multiple university startups and IP acquisition/acqui-hire deals. While working at UTEST\, Hassan is also the Chief Executive officer of Bitnobi\, Inc. which is a startup that has designed and developed a privacy protected\, data sharing platform. At Bitnobi\, Hassan manages all day-to-day business affairs for the company in order to help commercialize their solution. He holds an M.Sc from the International Space University and a BASc in Computer Engineering from the University of Ottawa. \n\n\n  \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nMathew Platt\, PhD\nAssociate Director\, Creative Destruction Lab \nMathew got his start at the University of Guelph with a PhD in Human Health and Nutritional Sciences following an undergraduate honors degree in Biomedical Sciences. A scientist by training\, his passions evolved through graduate school towards entrepreneurship and business development. These passions lead him to found the Guelph Chapter of the non-profit event-driven group called the Science to Business Network in the fall of 2018. After defending his PhD in early 2019\, Mathew explored his passion further as the Director of Business Development for the National Chapter of the Science to Business Network. It was through this position that he first learned about the Creative Destruction Lab (CDL) in Toronto. Hired first as a Venture Manager for the Health stream in February of 2020\, Mathew went on to hold positions as the Recruitment Lead for Health at Toronto\, the Site Venture Recruitment Lead\, the Stream Lead and Senior Venture Manager for Health\, and now the Associate Director of Health. Passionate about building bridges between academia and industry\, Mathew now leads the CDL-Toronto’s Health strategy for how to recruit and support science and technology-based health-tech startups. \n  \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nJ. Paul Santerre\, PhD\nCo-director of the Health Innovation Hub (H2i) \nProfessor J. Paul Santerre has published >200 peer reviewed publications and is a listed inventor on >70 patents in the area of medical polymers\, biodegradation\, protein and blood interactions with surfaces\, surface modification\, regenerative medicine\, and drug delivery. He is co-founder and current director of the Health Innovation Hub at the University of Toronto (a student focused entrepreneur training co-curricular program with > 500 client health science and biomedical engineering start-up companies to date that have generated > $109MCdn). He is a co-founder of Interface Biologics and current CSO for the company\, along with being a co-founder of five other start-up companies\, and has won multiple national awards for his achievements in enabling entrepreneurship. These awards have included Canada’s Governor General award for Innovation\, and the Professional Engineers of Ontario Entrepreneurship Award in 2017. He has been awarded with the Baxter Chair for Health Technology & Commercialization at the University Hospital Network. He was president of the 2016 World Biomaterials Congress held in Montreal Canada\, and has received multiple awards for his community activity including the 2016 Community award from the Canadian Biomaterials\, the 2018 President’s Impact Award from the University of Toronto. \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n  \nJennifer Doucet\, PhD\nCo-Founder\, Glusyn \nJennifer joined Dr. Keith Pardee’s lab in October 2020 to work on the pandemic response projects to help automate the glucose meter sensing technology for point-of-need use in collaboration with NRC-CRAFT. Prior to joining the Pardee lab\, she was working as an industry scientist on validation of new In-vitro diagnostics (IVD) products and completed a PhD in the Cell and Systems Biology department at University of Toronto in 2018. Using the technology developed in the Pardee lab\, Jennifer co-founded Glusyn\, a company developing accurate and low-burden diagnostics through cell-free synthetic biology-based technology that allows for on-site testing of infectious diseases using a repurposed glucose meter as a convenient and universal reader for gene circuit sensor outputs. Glusyn has been a part of the UTEST 2021 cohort and became an H2i company through PRiME and Medicine By Design’s Building a Biotech Venture program in early 2022. The company is co-lead by Jennifer herself\, along with Evan Amalficano (PhD Candidate)\, Dr. Moiz Charania (Research Associate) and Dr. Keith Pardee in the Leslie Dan Faculty of Pharmacy at the University of Toronto. \n\n\n\n\n\n\n\n\n\nMODERATOR\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nMilica Vukmirovic\nDirector\, External Programs & Partnerships\, PRiME \n\n\n\n\nREGISTER HERE
URL:https://bme.utoronto.ca/event/jump-start-workshop-accelerate-innovation-in-precision-medicine/
CATEGORIES:Events & Workshops
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220519T090000
DTEND;TZID=America/Toronto:20220519T170000
DTSTAMP:20220511T185830Z
CREATED:20220511T185830Z
LAST-MODIFIED:20220511T185830Z
UID:37015-1652950800-1652979600@bme.utoronto.ca
SUMMARY:Engineering Research Day 2022: Building a Sustainable Future
DESCRIPTION:A hybrid event presented by U of T Engineering \nJoin us on Thursday\, May 19\, 2022 9:00 am – 5:00 pm for U of T Engineering’s second annual Engineering Research Day. This year’s theme of Building a Sustainable Future spotlights the unique role engineering professionals play in building a brighter future for all and celebrates the local and global impacts of \nU of T Engineering’s sustainability-focused research accomplishments and collaborations. \nThis event is open to all students\, alumni\, staff and faculty at U of T Engineering\, as well as current and \nprospective partners and key stakeholders across the research ecosystem. Through virtual and \nin-person programming\, Engineering Research Day 2022 offers an unparalleled opportunity to learn\, \nexplore and connect. \nU of T Engineering continues to be Canada’s top-ranked engineering school and consistently ranks in the global top 20. Our faculty are international leaders in their fields\, innovative educators\, and dedicated \nmentors. U of T Engineering’s research strengths draw students and faculty from all over the world. \n\n \n“I am excited to welcome everyone to this year’s Engineering Research Day event – this year’s focus on \nSustainability crosses all disciplines of Engineering and will showcase how our researchers are driving impactful programs\, projects and initiatives\, not only here in Canada but globally. “  \n– Chris Yip\, Dean\, U of T Engineering \n\nThe program will feature: \n1. Interactive fireside chats with keynote speakers (hybrid) \n2. Panels on sustainability and resilience across different disciplines (hybrid) \n3. Student networking lunch (in-person only) \n4. Booths from U of T Engineering research centres and institutes (hybrid) \n5. Open networking reception (in-person only) \nEngaging panel sessions will include: \n\nPutting the Engineering in Environmental\, Social and Governance (ESG) Investing\nEngineering Resilient Healthcare Systems: Lessons from the Pandemic\nSustainable Talent: Educating the 21st Century Engineer\nClimate Positive & Sustainable Campus\n\n*In-person venue: Myhal Centre for Engineering Innovation & Entrepreneurship\, 55 St. George Street
URL:https://bme.utoronto.ca/event/engineering-research-day-2022-building-a-sustainable-future/
CATEGORIES:Events & Workshops
ATTACH;FMTTYPE=image/png:https://bme.utoronto.ca/wp-content/uploads/2022/05/FSf3ruFXsAY3urd.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220530T150000
DTEND;TZID=America/Toronto:20220530T170000
DTSTAMP:20220530T152312Z
CREATED:20220511T143954Z
LAST-MODIFIED:20220530T152312Z
UID:37004-1653922800-1653930000@bme.utoronto.ca
SUMMARY:Pitch Competition: Building a Biotech Venture program
DESCRIPTION: \nRegister to join the audience at the 2022 Pitch Competition!\nJoin us in-person on May 30 for the Building a Biotech Venture Pitch Competition to learn how the next generation of regenerative and precision medicine researchers are preparing to translate their discoveries toward impact.\nWatch as six trainee-led teams from the University of Toronto and its affiliated hospitals pitch their ventures to an expert panel of judges. The winning team will receive $25\,000\, and the second-place team will receive $10\,000 in research funding to advance their product concept.\nRegister now\nThe competition is the culmination of Medicine by Design’s Building a Biotech Venture program\, offered in partnership with Precision Medicine Initiative (PRiME)\, the Health Innovation Hub (H2i) and Talk Boutique. Over the last six months\, teams have worked with mentors to advance early-stage company concepts based on their research.\nCome cheer on these up-and-coming entrepreneurs as they showcase their innovative technologies!\nNOTE: This event will be held in-person in accordance with the University of Toronto’s COVID-19 policies. Masks are required in indoor spaces where physical distancing cannot be maintained.\nMeet the judges\nAlberto GalassoElla Korets-Smith Angela MacDonaldRobin QuirkAlberto Galasso  \n \nAlberto Galasso\, PhD\nProfessor of Strategic Management\nRotman School of Management\, University of Toronto\nRead more\nElla Korets-Smith\nElla Korets-Smith\, MBA\, MSc\nChief Business Officer\, Virica Biotech\nRead more\nAngela MacDonald\nAngela McDonald\, PhD\nEntrepreneur-in-Residence\, Versant Ventures\nRead more\nRobin Quirk\nRobin Quirk\, PhD\, MBA\nVice President\, Technology Sourcing & Venture Development\, CCRM\nRead more\nMeet the teams\nAzane Therapeutics\nDelivering the promise of RNA therapy.\nLab: Institute of Biomedical Engineering and Department of Immunology\, University of Toronto\nThis company’s product\, a delivery vehicle for mRNA-based therapies\, has the potential to make it possible for rare diseases to be treated with mRNA. The platform could also apply to regenerative medicine treatments such as stem cell reprogramming and inflammatory disorders.\nDTPX Therapeutics\nDeveloping immunotherapy against hibernating drug tolerant cancer cells for colorectal cancer patients.\nLab: Princess Margaret Cancer Centre\, University Health Network; and Donnelly Centre for Cellular and Biomolecular Research\, University of Toronto.\nWhen individuals are treated for colorectal cancer with standard chemotherapy\, a cell population that’s resistant to treatment can “hibernate” and re-emerge after treatment\, causing the tumour to relapse. DTXP Therapeutics aims to create a platform that can selectively target these hibernating cells to reduce the chance of relapse\, potentially benefiting many types of cancer. \nGlusyn Diagnostics\nAutomated PCR-free diagnostic systems for rapid\, low-cost\, distributed usage.\nLab: Leslie Dan Faculty of Pharmacy\, University of Toronto.\nWith mastitis in dairy cows as a use-case\, this teams aims to develop automated PCR-free diagnostic systems that are shelf-stable and have low manufacturing costs. \nA2O\nReprogramming for recovery.\nLab: Division of Anatomy\, University of Toronto.\nA2O has developed a type of gene therapy to convert toxic brain cells back into healthy cells to treat chronic neurodegenerative disease such as multiple sclerosis and Alzheimer’s disease\, as well as acute neurological injuries such as spinal cord injury. This therapy allows for a targeted approach that can be tailored to disease type\, stage or severity. \nOne Drug\nEnabling next generation drugs.\nLabs: Leslie Dan Faculty of Pharmacy\, University of Toronto; Institute of Biomedical Engineering\, University of Toronto; and Department of Chemistry\, University of Toronto. \nDeveloping clinical point-of-care diagnostic devices that will enable clinicians and drug developers identify patients at risk of adverse drug reactions and/or suboptimal drug response based on their genetic makeup. \nScivance\nDeveloping therapeutics for rare disease.\nLab: Department of Chemical & Physical Sciences\, University of Toronto Mississauga\nOnly five percent of rare diseases have treatments\, and a substantial portion of these rare diseases are caused by genes called fusion oncogenes. This team is developing a proprietary algorithm and multi-disciplinary pipeline which lies at the intersection of medicinal chemistry\, structural biophysics and molecular biology\, which can help develop treatments for these disease drivers.
URL:https://bme.utoronto.ca/event/pitch-competition-building-a-biotech-venture-program/
LOCATION:Leslie Dan Pharmacy Building Room PB B250\, 144 College St\, Toronto\, M5S 3M2\, Canada
CATEGORIES:Events & Workshops
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220531T110000
DTEND;TZID=America/Toronto:20220531T120000
DTSTAMP:20220510T195824Z
CREATED:20220510T192503Z
LAST-MODIFIED:20220510T195824Z
UID:36936-1653994800-1653998400@bme.utoronto.ca
SUMMARY:Reimagining the Jugular Venous Pressure: The Evolution of a Medical Technology Start-up
DESCRIPTION:Please join us for an ECHO webinar on Tuesday May 31\, 2022 (11 am – 12 pm EST) featuring Dr. Andrew J Smith (CSO and Co-Founder\, JVPLabs). Dr. Smith’s presentation entitled\, “Reimagining the Jugular Venous Pressure: The Evolution of a Medical Technology Start-up”\, will feature an overview of JVPLabs\, its technologies and the story behind its success. JVPLabs is a medical device company founded in 2016 by two physicians\, Dr. Andrew Smith (Emergency Medicine) and Dr. Jason Roberts (Cardiology). The focus of the company is to develop a leading edge non-invasive technology to improve and enable assessment of Congestive Heart Failure (CHF) patients via the JVP height\, in hospital and remotely\, at home. Please see attachment for more details.
URL:https://bme.utoronto.ca/event/reimagining-the-jugular-venous-pressure-the-evolution-of-a-medical-technology-start-up/
CATEGORIES:External Speaker Series
ATTACH;FMTTYPE=image/jpeg:https://bme.utoronto.ca/wp-content/uploads/2022/05/thumbnail_ECHO-Webinar-Andrew-J-Smith-JVPLabs-May-31-2022-Social-media-e1652210852247.jpg
ORGANIZER;CN="Translational Biology and Engineering Program (TBEP)":MAILTO:reception.tbep@utoronto.ca
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220531T130000
DTEND;TZID=America/Toronto:20220531T140000
DTSTAMP:20220609T150149Z
CREATED:20220525T131335Z
LAST-MODIFIED:20220609T150149Z
UID:37435-1654002000-1654005600@bme.utoronto.ca
SUMMARY:Faculty Search Candidate Talk
DESCRIPTION:This event will be in person only.
URL:https://bme.utoronto.ca/event/faculty-search-candidate-talk/
LOCATION:Medical Science Building\, Room 3153\, 1 King's College Circle\, Toronto\, Ontario\, M5S 1A8\, Canada
CATEGORIES:BME Faculty Search
END:VEVENT
END:VCALENDAR